AI can deliver gains of $21m per drug development programme, study finds
Artificial intelligence (AI)-based clinical monitoring agents can deliver gains of up to $21m per drug development programme, as well as …
Post
-
-
UK study finds sharp increase in type 2 diabetes incidence
Type 2 diabetes (T2D) has posed a formidable challenge to public health throughout high-income nations due to the high prevalence …
-
Taiho Oncology reports positive results in REZILIENT3 trial
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported that the global Phase III REZILIENT3trial assessing zipalertinib combined with platinum-based …
-
Podcast: Bringing diversity to Alzheimer’s trials
In recent years, the Alzheimer’s disease market has seen several developments, including the debut of the first disease-modifying therapies (DMTs), …
-
Sumitomo treats first patient in Phase I/IIa trial of DSP-3077
Sumitomo Pharma America has treated the first patient in its Phase I/IIa clinical trial of DSP-3077 for adults with non-syndromic …
-
Definium’s psychedelic prospects brighten further on Phase III success
Definium Therapeutics has notched another late-stage win for DT120 in generalised anxiety disorder (GAD) – further bolstering the drug’s market …
-
Belenos’ Keymed licensing deal delivers on Phase II win in rhinosinusitis
Belenos Biosciences’ bet worth up to $185m on Keymed Biosciences’ subcutaneous chronic rhinosinusitis with nasal polyps (CRSwNP) therapy is showing …
-
Why your manufacturing floor is your greatest compliance risk – and opportunity
Ask any life sciences quality leader where their biggest compliance headaches originate, and you might expect them to point to …
-
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
A patient who developed multidrug-resistant E. coli following a transplant has recovered following treatment with an investigational clustered regularly interspaced …
-
Arch Biopartners plans US expansion of LSALT peptide trial
Arch Biopartners is set to expand its Phase II clinical trial of the LSALT peptide, a drug candidate targeting cardiac …
-
First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy
Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene …
-
MoonLake’s nanobody boosts PsA indication hopes after Phase III success
MoonLake Immunotherapeutics’ sonelokimab has shown benefit in patients with psoriatic arthritis (PsA), with a Phase III trial meeting its primary …
-
Commercialising drugs in Europe: Lean models for first-time launchers
In 2025, 193 innovative drugs received approval in Europe, including 133 new molecular entities (NMEs). Over half – 56% - …
-
Silence’s stock soars on divesiran’s Phase II polycythaemia vera success
British biotech Silence Therapeutics has been making noise on the stock markets by posting 30% growth in its share price …
-
Tenax Therapeutics’ stock crashes on Phase III trial failure
Tenax Therapeutics’ stock dropped by nearly 90% after a Phase III trial of its oral therapy for pulmonary hypertension associated …
